© 2025 HSP News Service, L.L.C.
Nicolas Girard, MD, a thoracic oncologist at the Institut Curie, Paris, presented the results of an interim analysis of the open-label phase II COCOON study, at the European Lung Cancer Congress (ELCC) 2025.1 A readily available preventive regimen (the COCOON regimen) reduced moderate-to-severe...
Updates from several clinical trials of the EGFR tyrosine kinase inhibitor osimertinib across stages and settings of EGFR-mutated non–small cell lung cancer (NSCLC) were presented at the European Lung Cancer Congress (ELCC) 2025. The updated results from the phase III LAURA trial were presented by ...
There has been remarkable progress in treating EGFR-variant lung adenocarcinoma with tyrosine kinase inhibitors such as gefitinib, erlotinib, osimertinib, and afatinib. However, several important issues remain unresolved, including whether there remains a role for chemotherapy, who should receive a ...
Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape over the last decade for patients with non–small cell lung cancer (NSCLC), the agents can also stimulate uncontrolled immunity against normal tissues and organs, leading to a cascade of immune-related adverse...
In a pooled analysis of the phase II TRUST-I and TRUST-II trials reported in the Journal of Clinical Oncology, Pérol et al found that the oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib was highly active in ROS1-positive advanced or metastatic ...
A recent study published by Hooda et al in The Annals of Thoracic Surgery suggests that Medicaid expansion under the Affordable Care Act has significantly improved access to timely treatment and high-volume hospitals for patients with early-stage non–small cell lung cancer (NSCLC). These findings...
Individuals who reported exclusive use of combustible cigarettes as well as those who reported dual use of both cigarettes and e-cigarettes showed similarly high toxicant exposure, according to the results of a study published in Nicotine & Tobacco Research. Both groups of smokers showed higher ...
Patients with melanoma and lung cancer who have brain metastases may experience severe inflammatory reactions after receipt of immunotherapy drugs combined with radiation therapy, according to a recent study published by Vaios et al in JAMA Network Open. Study Methods and Results In this study,...
The U.S. Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne), a biosimilar to bevacizumab (Avastin), for intravenous use. Bevacizumab-nwgd is a recombinant humanized monoclonal antibody and a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks...
A whole-genome sequencing–based, error-corrected method for detecting cancer from blood samples could be more sensitive and accurate in monitoring disease status posttreatment among patients with cancer compared with prior methods, according to a recent study published by Cheng et al in Nature...
Many patients who are eligible for lung cancer screening do not receive it, but do receive preventative screenings for other cancer types, according to the results of a new study published by Potter et al in JAMA. Background Although lung cancer screening is recommended for certain individuals...
In a study reported as a research letter in JAMA Oncology, Rolle et al found increased overall adherence to the 2021 updated U.S. Preventive Services Task Force (USPSTF) lung cancer screening guidelines vs the prior guidelines. In 2021, the USPSTF updated lung cancer screening guidelines by...
A new consortium, the Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment (AGILE), has proposed a public health program of longitudinal chest computed tomography (CT) screenings among a global high-risk population of tobacco-exposed individuals utilizing...
In a UK prospective longitudinal cohort study (SUMMIT) reported in The Lancet Oncology, Bhamani et al found that large-scale, low-dose computed tomography (CT) screening for lung cancer is effective and “can be delivered efficiently” in a diverse high-risk population. As stated by the...
Tobacco control–driven reductions in smoking prevalence may have helped avert over 3.8 million lung cancer–related deaths and gain just over 76 million years of life between 1970 and 2022 in the United States, according to a recent study published by Islami et al in CA: A Cancer Journal for...
This is Part 3 of EGFR-Mutant NSCLC: Treatment Considerations for Early-Stage Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Stephen Liu, Tina Cascone, and Susan Scott discuss the treatment of unresectable EGFR-mutant non–small cell lung cancer (NSCLC). The patient is a 66-year-old woman with a right upper lobe lung mass found on a screening CT scan. She has a 37-year history of smoking and quit 6 years ago. PET scan showed a hypermetabolic right upper lobe mass and mediastinal adenopathy. Bronchoscopy confirms adenocarcinoma in the right upper lobe and contralateral mediastinal adenopathy in R4, R7, and L4. With biopsy-confirmed N3 adenopathy, the multidisciplinary team determines she has unresectable stage III NSCLC. In the conversation that follows, the faculty discuss the importance of obtaining molecular testing to ensure optimal management of unresectable NSCLC, the use of concurrent chemoradiation, the role of osimertinib consolidation therapy for patients with EGFR-mutant NSCLC, and their approach to surveillance.
This is Part 2 of EGFR-Mutant NSCLC: Treatment Considerations for Early-Stage Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Stephen Liu, Tina Cascone, and Susan Scott discuss the treatment of resectable EGFR-mutant non–small cell lung cancer (NSCLC). The patient is a 70-year-old man who presented with a persistent cough. Chest x-ray showed a right upper lobe ground glass infiltrate, and symptoms persisted following treatment with antibiotics. A CT scan revealed a suspicious right upper lobe lung nodule, which was hypermetabolic on PET scan with mild uptake in a right paratracheal lymph node. Bronchoscopy and endobronchial ultrasound revealed lung adenocarcinoma in the right upper node and R4 lymph node. He was offered neoadjuvant cisplatin plus pemetrexed plus pembrolizumab, but is seeking another opinion. In the conversation that follows, the faculty discuss the importance of molecular testing prior to initiating treatment with immunotherapy, how to navigate situations where repeat biopsy is necessary, the role of adjuvant osimertinib following resection for EGFR-mutant NSCLC, and more.
The long-term impact of diet on health has been well studied, leading to guidance about limiting the consumption of red meat, alcohol, and other foods associated with an increased risk of malignancies such as colorectal, breast, and liver cancers. Researchers at the University of Florida Health...
In an interim analysis of a Chinese phase III trial (HARMONi) reported in The Lancet, Xiong et al found that ivonescimab—a bispecific antibody against PD-1 and VEGF—significantly improved progression-free survival vs pembrolizumab in the first-line setting for patients with advanced PD-L1–positive...
The ADAURA trial findings showed a significant benefit in disease-free survival with the EGFR inhibitor osimertinib, compared to placebo, making it the recommended standard of adjuvant treatment in patients with EGFR-mutated non–small cell lung cancer (NSCLC) for up to 3 years after surgery. In a...
Researchers have uncovered a novel combination therapy leveraging the U.S. Food and Drug Administration (FDA)-approved KRAS inhibitor sotorasib and an experimental drug called FGTI-2734, which could improve the efficacy of precision medicine in patients with KRAS-mutated non–small cell lung cancer...
Studies have shown that not only does exposure to wildfire smoke, which contains fine particulate matter, increase the risk of developing lung cancer, it can also significantly reduce survival rates among patients recovering from lung cancer surgery. A large national study by researchers at the...
In a systematic review and meta-analysis reported in The Oncologist, Leite da Silva et al found plasma circulating tumor DNA (ctDNA) kinetics to be predictive of survival outcomes in patients with advanced non–small cell lung cancer (NSCLC) who were undergoing targeted therapy and immune checkpoint ...
In a Chinese phase II trial (HORIZON-Lung) reported in The Lancet Oncology, Li et al found that trastuzumab rezetecan, a novel antibody-drug conjugate, showed activity in patients with advanced HER2-positive non–small cell lung cancer (NSCLC). Trastuzumab rezetecan consists of a HER2-directed...
Based on results from the phase II SKIPPirr trial, the addition of 8 mg of dexamethasone to standard infusion-related reaction prophylaxis appeared to reduce the incidence of such events by approximately threefold in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who were...
As reported in the Journal of Clinical Oncology by Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, and colleagues, final results of the registrational phase I/II LIBRETTO-001 trial showed continued benefit of the RET receptor tyrosine...
Several cardiovascular risk factors such as advanced age and smoking history may be prevalent among patients with lung cancer at the time of diagnosis and may increase their risk of future cardiovascular disease, according to findings presented by Malozzi et al at the American College of...
Treatment with the HER2 × HER3 bispecific antibody zenocutuzumab-zbco appeared to be safe and active in patients with advanced NRG1 gene fusion–positive solid tumors, according to results from the registrational phase II eNRGy study published by Schram et al in The New England Journal of Medicine....
Although national guidelines, including ASCO’s palliative care guideline,1 call for the early integration of palliative and oncology care for patients with advanced cancer, only 36% of those with a very poor prognosis and 18% of those with a poor prognosis receive palliative care services.2 The...
As reported in the Journal of Clinical Oncology by Jänne et al, an interim analysis of the phase III EXCLAIM-2 trial showed no progression-free survival benefit with mobocertinib—an EGFR tyrosine kinase inhibitor (TKI) targeting EGFR exon 20 insertion (ex20ins) mutations—compared with...
The Lung Cancer Master Protocol (Lung-MAP) is an innovative clinical trial designed to efficiently address the unmet needs of patients with advanced non–small cell lung cancer (NSCLC) following front-line therapy. This pioneering effort was the first biomarker-driven umbrella master protocol...
Investigators have found that although fewer patients may be diagnosed with and dying from cancer in Appalachia, cancer incidence and mortality rates remain substantially higher compared with elsewhere in the United States, according to a recent study published by Burus et al in the Journal of the...
Researchers may have uncovered a novel strategy to help predict how well patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC) will respond to new therapies, according to a recent study published by Kato et al in Clinical Cancer Research. Study Methods and Results Researchers developed ...
As reported in the Journal of Clinical Oncology by Awad et al, exploratory analysis of the comparison of neoadjuvant nivolumab/ipilimumab vs chemotherapy in the phase III CheckMate 816 trial found that nivolumab/ipilimumab was associated with numerically better event-free survival in patients with...
Anatomic lung resections such as lobectomy and segmentectomy may be associated with improved long-term survival in patients with early-stage non–small cell lung cancer (NSCLC) compared with wedge resection, according to new findings presented at the 2025 Society of Thoracic Surgeons (STS) Annual...
In a Chinese phase II study (C-Brain) reported in The Lancet Oncology, Xu et al found that brain radiotherapy in combination with camrelizumab and platinum-doublet chemotherapy produced “promising” results in patients with previously untreated advanced non–small cell lung cancer (NSCLC) with brain...
For more than a year before my diagnosis of stage IA non–small cell lung cancer (NSCLC), in 2020, I had been self-treating a relentless chronic cough and a slight feeling of tightness in my chest. The symptoms were similar to asthma, so I began using albuterol inhalers. When they stopped working, I ...
Lung cancer is the second most common cancer in the United States, but high recurrence rates persist for patients with early-stage disease. A recent study published by Black et al in Nature Medicine has found that even very low traces of circulating tumor DNA (ctDNA) may be linked to increased...
Lung cancer is the second most common cancer, excluding skin cancer, diagnosed in men and women in the United States. And despite advances in treatment for the disease, which have led to improved survival rates, lung cancer remains the leading cause of cancer mortality in the United States, with...
Although lung cancer and related cancer deaths decreased in the world’s 10 most populous countries from 1990 to 2019, these positive statistics may not address trends in mortality linked to tobacco use, air pollution, and asbestos exposure, according to a recent study published by Jani et al in...
As reported in the Journal of Clinical Oncology by Sands et al, the phase II TROPION-Lung05 trial showed “encouraging activity” of datopotamab deruxtecan (Dato-DXd) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) with actionable genomic alterations whose disease progressed...
The ORACLE test may be capable of predicting lung cancer survival at the point of diagnosis more effectively than currently used clinical risk factors, according to a recent study published by Biswas et al in Nature Cancer. The findings could help physicians make more informed treatment decisions...
In a phase II trial reported in The Lancet Oncology, Heinzerling et al found that primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemoradiotherapy (with or without adjuvant immunotherapy) was associated with activity in patients with locally advanced...
On December 18, 2024, the U.S. Food and Drug Administration (FDA) approved the anaplastic lymphoma kinase (ALK) inhibitor ensartinib (Ensacove) for adults with ALK-positive locally advanced or metastatic non–small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor. For full...
This is Part 2 of Clinical Perspectives on KRAS-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Gregory Riely, Rebecca Heist, and Joshua Sabari discuss the second-line treatment of a patient with KRAS-mutant metastatic non–small cell lung cancer (NSCLC). The patient is a 67-year-old woman who is diagnosed with lung adenocarcinoma with oligoprogressive disease, PD-L1 expression of 10%, and KRAS G12C, STK11, and KEAP1 mutations. She receives initial therapy with chemotherapy and dual checkpoint inhibition but shows evidence of disease progression after 8 cycles of therapy. In the conversation that follows, the faculty discuss the local treatment options for oligoprogressive KRAS G12C–mutant lung cancer after disease progression, how the currently approved KRAS G12C inhibitors compare with docetaxel, and treatment considerations when using KRAS inhibitors.
This is Part 1 of Clinical Perspectives on KRAS-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Gregory Riely, Rebecca Heist, and Joshua Sabari discuss the first-line treatment of a patient with KRAS-mutant non–small cell lung cancer (NSCLC). The patient is a 58-year-old woman who presents with bilateral lung masses and is found to have diffusely metastatic lung adenocarcinoma with KRAS G12D, TP53, and STK11 mutations, and a PD-L1 expression of 30%. In the conversation that follows, the faculty discuss the importance of upfront testing for all genomic alterations, whether all KRAS mutations are actionable, and the role of tumor histology and PD-L1 status in determining appropriate first-line therapy.
In a phase II trial reported in The Lancet Oncology, Heinzerling et al found evidence of efficacy of primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemotherapy and consolidative immunotherapy in patients with locally advanced non–small cell lung cancer...
Metformin may strengthen the effects of immunotherapy and improve recurrence-free survival in patients with lung cancer with overweight or obesity, according to a recently published article in the Journal of the National Cancer Institute.1 The investigators looked at data from two groups of...
On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to the HER2 × HER3 bispecific antibody zenocutuzumab-zbco (Bizengri) for adults with the following types of lung and pancreatic cancers: advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC)...
“Artificial intelligence [AI] will be used in all aspects of [lung cancer] screening…, and it continues to get better,” commented topic overview speaker David F. Yankelevitz, MD, Professor of Radiology at the Icahn School of Medicine at Mount Sinai, New York, at the Quantitative Imaging Workshop...